616 Krankheiten
Refine
Has Fulltext
- yes (173) (remove)
Is part of the Bibliography
- yes (173)
Year of publication
Document Type
- Journal article (173) (remove)
Language
- English (173)
Keywords
- breast cancer (6)
- Fabry disease (5)
- Parkinson’s disease (4)
- dopamine (4)
- follow-up (4)
- oxidative stress (4)
- quality of life (4)
- schizophrenia (4)
- MRI (3)
- Mice (3)
- antibodies (3)
- brain (3)
- chronic kidney disease (3)
- enzyme replacement therapy (3)
- gene (3)
- genetics (3)
- heart failure (3)
- hypertrophic cardiomyopathy (3)
- magnetic resonance imaging (3)
- mice (3)
- mortality (3)
- mouse model (3)
- prognosis (3)
- survival (3)
- ADHD (2)
- AIDS (2)
- B cells (2)
- CSF (2)
- Fabry (2)
- Fabry nephropathy (2)
- Fabry-associated pain (2)
- HIV (2)
- IL-10 (2)
- Inflammation (2)
- P300 (2)
- Pain (2)
- Parkinson disease (2)
- Parkinson's disease (2)
- Therapy (2)
- anxiety (2)
- back pain (2)
- basal ganglia (2)
- biomarker (2)
- biomarkers (2)
- cancer treatment (2)
- cardiovascular disease (2)
- cardiovascular events (2)
- cell cultures (2)
- children (2)
- coronary heart disease (2)
- deep brain stimulation (2)
- depression (2)
- disease (2)
- epidemiology (2)
- expression (2)
- family (2)
- fibrosis (2)
- fracture (2)
- gastric cancer (2)
- gene expression (2)
- genome-wide association (2)
- hearing loss (2)
- hemodialysis (2)
- hip (2)
- hospitalization (2)
- human immunodeficiency virus (2)
- impact (2)
- infection (2)
- inflammation (2)
- leukemia (2)
- lung (2)
- lung cancer (2)
- magnetic resonance (2)
- major depressive disorder (2)
- melanoma (2)
- messenger RNA (2)
- metaanalysis (2)
- multiple sclerosis (2)
- mutation (2)
- myasthenia gravis (2)
- myocardial infarction (2)
- oncolytic viruses (2)
- osteoarthritis (2)
- osteoporosis (2)
- population (2)
- predictors (2)
- prevalence (2)
- prostate cancer (2)
- protein (2)
- pulmonary embolism (2)
- randomized controlled trial (2)
- risk (2)
- risk factors (2)
- sepsis (2)
- shock (2)
- stroke (2)
- surgery (2)
- susceptibility (2)
- teriparatide (2)
- therapy (2)
- treatment (2)
- trial (2)
- update (2)
- validation (2)
- validity (2)
- ventilation (2)
- walking (2)
- 1p13.3 (1)
- 1q21 (1)
- 1st International Workshop (1)
- 2B (1)
- 5-Fluorouracil (1)
- 5IA-SPECT (1)
- 7q11.2 (1)
- A53T (1)
- ADAMTS (1)
- ALS (1)
- Acute Myocardial Infarction (1)
- Adrenocortical Carcinoma (1)
- Agalsidase beta therapy (1)
- Akutes Nierenversagen (1)
- Alpha galactosidase (1)
- Alzheimer's disease (1)
- Alzheimer’s disease (1)
- Amino acids (1)
- Anderson-Fabry Disease (1)
- Ankyrin (1)
- ApoE\(^{(-/-)}\) (1)
- Arterial water (1)
- Attention-deficit/hyperactivity disorder (1)
- B lymphocytes (1)
- B-cell lymphoma (1)
- BCI (1)
- BK virus (1)
- BRAF mutation (1)
- BRCA1 (1)
- Barrett-Ösophagus (1)
- Barthel-Index (1)
- Bessle functions (1)
- Beta-glucocerebrosidase (1)
- Biomarkers (1)
- Blood-brain barrier (1)
- Brain (1)
- Breast cancer (1)
- Breast-tumors (1)
- C-MYC (1)
- CBF (1)
- CD4 T cells (1)
- CMV (1)
- CNO (1)
- CRMO (1)
- Capicua transcriptional repressor (1)
- Cardiovascular Magnetic Resonance (1)
- Charcot–Marie–Tooth disease (1)
- Chemotherapy (1)
- Childhood (1)
- Clinical manifestations (1)
- Coefficient (1)
- Comorbidities (1)
- Comorbidity survey replication (1)
- D313Y genotype (1)
- DAT (1)
- DIRA (1)
- DNA (1)
- DNA Methylation (1)
- DRD2 (1)
- DSM-5 (1)
- DSM-IV (1)
- DSM-IV disorders (1)
- Deflazacort (1)
- Demyelinating peripheral neuropathy (1)
- Depression (1)
- Diagnosis (1)
- Disease (1)
- Disease progression (1)
- Disease-modifying therapies (1)
- Draize eye test (1)
- Drug development (1)
- Drug resistance (1)
- Duchenne dystrphy (1)
- E3 ubiquitin ligase (1)
- EAU guidelines (1)
- EBV (1)
- EDS (1)
- ELISPOT (1)
- ENV (1)
- EORTC-BN20 (1)
- EORTC-QLQ-C15-PAL (1)
- EQ-5D (1)
- EUROASPIRE survey (1)
- Early-onset (1)
- Ehlers-Danlos syndrome (1)
- Enzyme replacement therapy (1)
- Enzyme-Linked Immunospot assay (ELISPOT) (1)
- Epilepsy (1)
- Epstein-Barr-virus (1)
- Experimental stroke (1)
- Extramedullary disease (1)
- F-19 MRI (1)
- FDG (1)
- FDG-PET/CT (1)
- FDG-PET/MRI (1)
- FP-CIT SPECT (1)
- Fabry cardiomyopathy (1)
- Fabry patient (1)
- Follow-up (1)
- Fontan’s Operation (1)
- Frabin/Fgd4 (1)
- GLA protein UCMGP (1)
- GP41 cytoplasmic tail (1)
- Gene-expression (1)
- HAND (1)
- HCMV infection (1)
- HE-3 diffusion MRI (1)
- HER2 (1)
- Haemodialysis (1)
- Heart failure (1)
- Heart failure with preserved ejection fraction (1)
- Heart failure with reduced ejection fraction (1)
- Helicobacter pylori (1)
- Hepatitis C infection (1)
- Hodgkin-lymphoma (1)
- Homoarginine (1)
- Hurst Exponent (1)
- ICD-coding of CKD (1)
- IFN-γ (1)
- IL-2 (1)
- IL28B (1)
- IMpACT (1)
- Illumina Human Exome Bead Chip (1)
- Images (1)
- In-vivo (1)
- Infarct Zone (1)
- Insulin Degrading Enzyme (1)
- Iron Oxide Nanoparticle (1)
- Iron-oxide (1)
- Iron-uptake (1)
- Krebs (1)
- L-arginine (1)
- LC-ESI/MS/MS (1)
- LIMP-2 (1)
- LPHN3 (1)
- LV mass (1)
- Lesions (1)
- Lewy-like pathology (1)
- Limb girdle muscular dystrophy (LGMD) (1)
- Lipom (1)
- Lyso-Gb3 (1)
- MCPH1 (1)
- MRI reporter (1)
- MS (1)
- MTCH2 (1)
- Magnetic-resonance (1)
- Majeed (1)
- Metaanalysis (1)
- MicroRNAs (1)
- Miyoshi myopathy (1)
- Morbus Fabry (1)
- Multiple myeloma (1)
- Multiple sclerosis (1)
- Mycobacterium caprae (1)
- Mycobacterium tuberculosis complex (1)
- N-Myc down regulated gene 1 (1)
- NADPH oxidase inhibitors (1)
- NADPH oxidases (NOX) (1)
- NCAM1 (1)
- NMO-IGG (1)
- NPU (1)
- NRG1 (1)
- Neuropathy (1)
- Neuroprotection (1)
- Normal breast (1)
- OECD guideline (1)
- OncotypeDX\(^{®}\) (1)
- Outcome survey (1)
- Ovarian (1)
- P. falciparum (1)
- PAI-1 (1)
- PAPA (1)
- PDH (1)
- PET/CT (1)
- PSMA (1)
- Parkinson (1)
- Parkinsons disease (1)
- Particles (1)
- Perfusion (1)
- Pharmacological management (1)
- Physical impairment (1)
- Prevalence (1)
- Primary cell lines (1)
- Prostatakrebs (1)
- Proteins (1)
- Pycnogenol (1)
- Quality of life (1)
- RDoC (1)
- RNA interference (1)
- Randomized controlled trial (1)
- Rats (1)
- Rho-GTPase Cdc42 (1)
- Rochester diabetic neuropathy (1)
- SAH (1)
- SCD (1)
- SCF (1)
- SKP1 (1)
- SVR (1)
- Salmonella-typhimurium (1)
- Scale (1)
- Short dsRNA oligonucleotides (1)
- Small-fiber neuropathy (1)
- Soft-tissue infection (1)
- Stem cells plasticity (1)
- Strahlentherapie (1)
- Sudden cardiac death (1)
- Sugar-transport (1)
- Superparamagnetic Iron Oxide (1)
- Surrogate endpoints (1)
- T-DM1 (1)
- T-PA (1)
- T-cell reactivity (1)
- TIC disorders (1)
- TLR4 (1)
- TNF-α (1)
- Thyroid cancer (1)
- Tissue engineering (1)
- Tracking (1)
- Treatment (1)
- Trypanosoma (1)
- Tuberkulose (1)
- UME6 (1)
- United States (1)
- V. saphena magna (1)
- VAL66MET polymorphism (1)
- Virologie (1)
- Von-Willebrand-factor (1)
- WB-DW-MRI (1)
- ablation (1)
- accuracy (1)
- acetylsalicylic acid exacerbated respiratory disease (1)
- acoustic startle (1)
- acquired immunodeficiency-syndrome (1)
- activation (1)
- acute (1)
- acute ischemic stroke (1)
- acute kidney injury (1)
- acute liver failure (1)
- acute management of stroke (1)
- acute neurology (1)
- acute stroke imaging (1)
- acute stroke management (1)
- acute stroke outcome (1)
- adalimumab (1)
- adjuvant (1)
- adrenal cortex hormones (1)
- adrenal cortex neoplasms (1)
- adrenal imaging (1)
- adrenal tumours (1)
- adult (1)
- adulthood (1)
- aerobic glycolysis (1)
- agalsidase-beta (1)
- age (1)
- alendronate (1)
- alkaline phosphatase (1)
- allergic rhinitis (1)
- allografts (1)
- alpha galactosidase (1)
- alpha-galactosidase A (1)
- alpha-galactosidase-A (1)
- alpha-synuclein (1)
- alternatives (1)
- alveolar (1)
- amyotrophic lateral sclerosis (1)
- animal model (1)
- animal models (1)
- anti-aquaporin-4 antibody (1)
- antigen (1)
- antioxidant function (1)
- antirheumatic agents (1)
- aortic valve (1)
- aortic valve disease (1)
- apomorphine (1)
- apoptosis (1)
- aquaporin-4 autoantibodies (1)
- argeted therapy (1)
- arm (1)
- artery occlusion (1)
- arthritis (1)
- arthroplasty (1)
- aspirin sensitivity (1)
- aspirin-induced asthma (1)
- association (1)
- asthma (1)
- astrocytic tumor (1)
- atypical (1)
- auditory (1)
- autism (1)
- autoimmunity (1)
- autonomous cortisol secretion (1)
- awareness (1)
- axonopathic changes (1)
- axons (1)
- beta oscillations (1)
- beta-TRCP (1)
- binding (1)
- binge eating (1)
- bioinformatics (1)
- biopsy findings (1)
- biosynthesis (1)
- bipolar disorder (1)
- blood biomarker (1)
- blood brain barrier (1)
- blood-glucose control (1)
- bone (1)
- bone colonization (1)
- bone formation (1)
- bone marrow transplantation (1)
- bone-mineral density (1)
- brain cancer (1)
- brain computer interface (1)
- brain edema (1)
- brain tumours (1)
- calcium (1)
- cancer (1)
- cancer patients (1)
- carcinomas (1)
- cardiac energy metabolism (1)
- cardiac hypertrophy (1)
- cardiac magnetic resonance imaging (1)
- cardiogenic (1)
- cardiopulmonary exercise testing (1)
- cardiovascular care (1)
- cardiovascular magnetic-resonance (1)
- cardiovascular morbidity (1)
- cardiovascular risk factors (1)
- cartilage (1)
- cell cycle (1)
- cell-cycle arrest (1)
- cells (1)
- cellular proteins (1)
- central nervous system (1)
- cerebrospina (1)
- cerebrospinal fluid culture (1)
- cerebrospinal-fluid (1)
- chemical properties (1)
- chemotherapy (1)
- childhood cancer (1)
- chip analyses (1)
- chronic distress (1)
- chronic heart failure (1)
- chronic kidney-disease (1)
- chronic thromboembolic pulmonary hypertension (1)
- chronic viral infection (1)
- classification (1)
- clinical (1)
- clinical diagnosis (1)
- clinical study (1)
- clinical trials (1)
- clinical-practice (1)
- coefficient (1)
- cognitive decline (1)
- collarless (1)
- colony-stimulating factor (1)
- colorectal cancer (1)
- common SNPS (1)
- complex diseases (1)
- complex disorders (1)
- complication (1)
- comprehensive management (1)
- comprehensive psychosomatic assessment (1)
- computed tomography (1)
- consortium (1)
- contrast-enhanced MRI (1)
- controlled clinical-trials (1)
- coordination (1)
- copy number variants (1)
- cornea verticillata (1)
- corneal equivalent (1)
- coronary artery disease (1)
- coronary calcification (1)
- coronary-artery calcification (1)
- coverage (1)
- crantiectomy (1)
- craving (1)
- creatine synthesis (1)
- critically ill (1)
- cryptogenic stroke (1)
- cue (1)
- cystic fibrosis (1)
- cytokine (1)
- cytokine secretion kinetics (1)
- cytomegalovirus (1)
- damage responses (1)
- darbepoetin alpha (1)
- database (1)
- decompressive surgery (1)
- degeneration (1)
- dehydrogenases (1)
- dendritic cells (1)
- dentate gyrus (1)
- dependency (1)
- design (1)
- dexamethasone suppression test (1)
- diabetes complications (1)
- diabetes mellitus (1)
- diabetes mellitus type 2 (1)
- diabetic mouse (1)
- diabetic nephropathy (1)
- diagnosis (1)
- dialysis (1)
- differentially expressed genes (1)
- differentiation (1)
- diffusion weighted MRI (1)
- diffusion-weighted MRI (1)
- disease progression (1)
- disease-modifying therapies (1)
- disorder (1)
- dolutegravir (1)
- dopamine acetylcholine (1)
- double-blind (1)
- drug development (1)
- duchenne muscular dystrophy (1)
- duodenal levodopa infusion (1)
- dysferlinopathy (1)
- dyspnea (1)
- early diagnosis (1)
- ejection fraction (1)
- electroporation (1)
- elispot (1)
- elucidation (1)
- embolic stroke (1)
- emotional regulation (1)
- emtricitabine (1)
- encephalitis dementia (1)
- end stage renal disease (1)
- endocrinology (1)
- endogenous psychoses (1)
- endophenotype (1)
- endotheliopathy (1)
- endotoxemia (1)
- entorhinal cortex (1)
- environment (1)
- enzyme-linked immunoassays (1)
- epigastric hernia (1)
- epimutation (1)
- eukaryota (1)
- euroaspire (1)
- exacebrated respiratory-disease (1)
- exhaustion (1)
- experimental (1)
- experimental autoimmune encephalomyelitis (1)
- expression pattern (1)
- extensiv transverse myelitis (1)
- extracellular matrix (1)
- extracellular matrix remodeling (1)
- extracorporeal membrane oxygenation (1)
- eye irritation testing (1)
- fMRI (1)
- factor expression (1)
- fatty liver disease (1)
- fear of progression (1)
- feasibility (1)
- femoral revision (1)
- fetuin A (1)
- fibrosis progression (1)
- field (1)
- fluid (1)
- fluorescent-probes (1)
- focal cerebral ischemia (1)
- focal semental glomerulosclerosis (1)
- folinic acid (1)
- food addiction (1)
- fosfomycin (1)
- foxes vulpes-vulpes (1)
- frontal cortex (1)
- functional imaging (1)
- functional neuroanatomy (1)
- gadofluorine (1)
- gadolinium-DTPA (1)
- gait (1)
- gait analysis (1)
- gambling (1)
- gastroesophageal reflux (1)
- gastroesophageal reflux disease (1)
- gemcitabine (1)
- gene ontology (1)
- gene-environment interaction (1)
- genetic heterogeneity (1)
- genetic interaction (1)
- genetic modifiers (1)
- genetic renal disease (1)
- genetic risk factor (1)
- genetic variation (1)
- genome-wide association study (GWAS) (1)
- genomic damage (1)
- germinal center (1)
- giant ventral hernia (1)
- gilles (1)
- glioblastoma cell-lines (1)
- glioblastoma multiforme (1)
- glomerular-filtration-rate (1)
- glucose transporter (1)
- glycoprotein incorporation (1)
- granzyme B (1)
- green fluorescent protein (1)
- gridle muscular-dystrophy (1)
- group-B (1)
- growth (1)
- growth factor (1)
- guideline adherence (1)
- guideline implementation (1)
- guidelines (1)
- haplogroups (1)
- hcv infection (1)
- health care research (1)
- health questionnaire (1)
- health-related quality of life (1)
- heat shock protein Hsc-70 (1)
- helminths (1)
- hematopoietic (1)
- hematopoietic stem cells (1)
- hemicraniectomy (1)
- heptacellular carcinoma (1)
- hereditary motor and sensory neuropathy (1)
- heritability (1)
- herpes virus (1)
- hospital medical complications (1)
- host genetics (1)
- human (1)
- human cancer diseases (1)
- human cytomegalovirus (HCMV) (1)
- human diseases (1)
- humanized bone models (1)
- hyperpolarized HE-3 (1)
- hyponatremia (1)
- imaging mass spectrometry (1)
- immune neuromelanin (1)
- immune response (1)
- immune suppression (1)
- immune-response (1)
- immunity (1)
- immunoglobulin-G (1)
- immunohistochemistry (1)
- immunology and microbiology section (1)
- impaction bone grafting (1)
- impulse control disorders (1)
- in situ guided tissue regeneration (1)
- in vivo (1)
- incisional hernia (1)
- induced insulin-release (1)
- infants (1)
- infectious-disease diagnostics (1)
- infiltrate (1)
- inflammatory diseases (1)
- inguinal lymph node dissection (1)
- inherited metabolic disorders (1)
- inhibitor (1)
- initial experience (1)
- insulin (1)
- insulin receptor (1)
- insulin-like growth factor 1 receptor (1)
- integrase inhibitor (1)
- interval timing (1)
- intractable hiccup (1)
- invasive cysticerocsis (1)
- involvement (1)
- irinotecan (1)
- iron oxide nanoparticles (1)
- ischaemic stroke (1)
- ischemic stroke (1)
- journals (1)
- juvenile idiopathic arthritis (1)
- kidney (1)
- kidney neoplasms (1)
- kidney-disease CKD (1)
- kidneys (1)
- kinases (1)
- kinematics (1)
- kinetics (1)
- knees (1)
- laparostomy (1)
- late gadolinium enhancement (1)
- latency (1)
- left lateral wall (1)
- left ventricular mass (1)
- left-ventricular hypertrophy (1)
- lipid desaturation (1)
- lipidomics (1)
- lipoxygenase (1)
- liver resection (1)
- locally advanced disease (1)
- loci (1)
- locus coeruleus (1)
- lovastatin (1)
- lung and intrathoracic tumors (1)
- lymph nodes (1)
- lymphoma (1)
- lysosomal storage disease (1)
- mTOR-inhibitor RAD-001 (1)
- magnetic resonance spectroscopy (1)
- magnetic resonsance imaging (1)
- magnetic-resonance behavior (1)
- magnetic-resonance-spectroscopy (1)
- malaria (1)
- malignant MCA infarct (1)
- malignant lymphoma (1)
- malignant melanoma (1)
- management (1)
- maritime pine bark extract (1)
- mass spectrometry (1)
- matrix metalloproteinase (1)
- measles (1)
- mechanical energy (1)
- mechanisms (1)
- memory (1)
- memory cells (1)
- memory deficits (1)
- meningococcal disease (1)
- meningococcal polysaccharides (1)
- mesenchymal tissues (1)
- metabolism (1)
- metabolomics (1)
- metastasis (1)
- microRNAs (1)
- microRNA–target interaction (1)
- microangiopathy (1)
- microarray (1)
- microarrays (1)
- microcephalin 1 (1)
- microdeletion (1)
- migraineur (1)
- mineral metabolism (1)
- mineralocorticoid antagonist (1)
- missing heritability (1)
- mitochondria (1)
- modular (1)
- modulation (1)
- molecular genetics (1)
- molecular medicine (1)
- monozygotic twins (1)
- mood disorder (1)
- morbidity (1)
- morphogenesis (1)
- morphometry (1)
- motor function (1)
- mouse models (1)
- movements (1)
- multicenter (1)
- multigene-array (1)
- multimodal (1)
- multiple diseases (1)
- multiple myeloma (1)
- multiple system atrophy (1)
- multiple-sclerosis (1)
- murine gammaherpesvirus 68 (1)
- muscle strength (1)
- mutant p53 (1)
- myelin (1)
- myelination (1)
- myeloid (1)
- myocardial lipid content (1)
- nab-paclitaxel (1)
- national health survey (1)
- natural-history data (1)
- neoadjuvant (1)
- neoadjuvant chemotherapy (1)
- nerve fibers (1)
- nerve ultrasonography (1)
- nervous system (1)
- neural apoptosis (1)
- neural stem cells (1)
- neuregulin-1 (1)
- neuroinflammation (1)
- neuromelanin (1)
- neuron navigator 3 (1)
- neuroprotection (1)
- neuropsychiatric disorders (1)
- neurotrophic factor (1)
- neurotrophic factor gene (1)
- nicotinic receptors (1)
- nictric-oxide (1)
- noradrenalin (1)
- norepinephrine (1)
- nuclear antigen (1)
- nuclear magnetic resonance (1)
- nucleus (1)
- nucleus accumbens (1)
- number (1)
- obesity (1)
- observational study (1)
- oligonucleotides (1)
- open abdomen (1)
- optical coherence tomography (1)
- oral anticancer drugs (1)
- outcomes (1)
- overdose (1)
- oxaliplatin (1)
- p53-dependent apoptosis (1)
- p53-inducible regulator (1)
- pain (1)
- pain questionnaire (1)
- pancreatic cancer (1)
- parkinson disease (1)
- particles (1)
- partitioning analysis RPA (1)
- patient (1)
- patients’ awareness (1)
- pediatric (1)
- peptide vaccination (1)
- peripheral neuropathy (1)
- persistence (1)
- persistent ADHD (1)
- perspectives (1)
- pet (1)
- pharmacotherapy (1)
- phase contrast (1)
- phenotype (1)
- phosphodiesterase (1)
- physicians’ awareness (1)
- pine bark extract (1)
- plasma membrane (1)
- plasmid construction (1)
- plasmodium falciparum (1)
- platelet dysfunction (1)
- podocyte (1)
- point-of-care echocardiography (1)
- polymorphism (1)
- polymorphisms (1)
- polyomavirus (1)
- polyphenols (1)
- porous-coated stems (1)
- postoperativ (1)
- prednisone (1)
- preserved ejection fraction (1)
- prevalent fractures (1)
- prognostic index (1)
- progression (1)
- proliferation (1)
- prostatic neoplasms (1)
- prosthesis (1)
- proteasome (1)
- protein-protein interaction network (1)
- proteinuria (1)
- proteolipid protein gene (1)
- proton (1)
- psychiatric disorders (1)
- psychopathology (1)
- pulmonary artery (1)
- pulmonary artery pressure (1)
- pulmonary circulation (1)
- pulmonary hypertension (1)
- pulse wave velocity (1)
- pulses (1)
- qPCR (1)
- quality indicators (1)
- quality of health care (1)
- quality-of-care (1)
- radiation oncology (1)
- radical cystectomy (1)
- radiotherapy (1)
- randomized controlled study (1)
- rankin scale (1)
- rare diseases (1)
- rat (1)
- rat kidney (1)
- recurrence (1)
- recurrent Tako-Tsubo cardiomyopathy (1)
- reflex (1)
- regenerative medicine (1)
- regional recurrence (1)
- registries (1)
- registry (1)
- regression analysis (1)
- regulator (1)
- regulatory T cell (1)
- reliability (1)
- renal cancer (1)
- renal fibrosis (1)
- renal function (1)
- renal osteodystrophy (1)
- replacement (1)
- replacement therapy (1)
- respiratory virus (1)
- response evaluation (1)
- responsiveness (1)
- resting tremor (1)
- restoration (1)
- resveratrol (1)
- retinal ganglion cells (1)
- retinocochleocerebral (1)
- retrospective study (1)
- revision (1)
- rheumatoid (1)
- right inferior frontalgyrus (1)
- risk factor (1)
- risk-factors (1)
- roentgenographic assessment (1)
- rolipram (1)
- salvage radiotherapy (1)
- scaffolds (1)
- scale (1)
- sclerostin (1)
- screening for distress (1)
- search filter (1)
- secondary brain damage (1)
- secondary cancer (1)
- secondary lung tumors (1)
- self-diffusion (1)
- senescence (1)
- septal hypertrophy (1)
- septic (1)
- sequence imaging protocol (1)
- sequence variations (1)
- serogroup-Y (1)
- serotonin (1)
- serum (1)
- serum creatinine (1)
- severity (1)
- signature (1)
- single-nucleotide polymorphisms (1)
- small interfering RNAs (1)
- somatic mosaicism (1)
- spectrum disorders (1)
- spinal cord (1)
- spinal-cord (1)
- sporadic Parkinson's disease (1)
- stage renal-disease (1)
- staib agar (1)
- standardization (1)
- stem cells (1)
- steroids (1)
- streptozotocin (1)
- stroke register (1)
- stroke therapy (1)
- stroke unit (1)
- stroke unit care (1)
- structural determination (1)
- substance dependence (1)
- substance use disorder (1)
- substantia nigra (1)
- subthalamic nucleus (1)
- sudden cardiac death (1)
- suicide attempt (1)
- superficial peroneal nerve (1)
- sural nerve (1)
- surrogate endpoints (1)
- surveillance (1)
- survival analysis (1)
- survivin (1)
- sustained fear (1)
- symptoms (1)
- synovial fluid (1)
- synovitis (1)
- synthetic mesh (1)
- systolic dysfunction (1)
- tapered stem (1)
- targeted (1)
- task force (1)
- tenofovir disaproxil fumarate (1)
- term mortality (1)
- territory infaction (1)
- testicular neoplasms (1)
- therapeutic strategy (1)
- thymic carcinoma (1)
- thymoma (1)
- thymus (1)
- tinnitus (1)
- tissue engineering (1)
- transcranial direct current stimulation (1)
- transfection (1)
- transforming growth factor-beta 1 (1)
- translational stroke research (1)
- transplantation (1)
- transverse relaxation (1)
- treatment outcome (1)
- treatment response (1)
- treg cells (1)
- tremor (1)
- tuberculous meningitis (1)
- tumor (1)
- tumor stem cells (1)
- tumor-draining lymph node (1)
- tumorigenesis (1)
- twin study (1)
- type-1 matrix (1)
- uPA (1)
- ubiquitin (1)
- umbilical hernia (1)
- univentricular heart (1)
- urinary bladder neoplasms (1)
- urinary protein excretion (1)
- urine (1)
- vaccination (1)
- vaccines (1)
- vaccinia virus (1)
- vacuum conditioning (1)
- variants (1)
- varicella (1)
- vascular calcification (1)
- vascular type (1)
- vasculitis (1)
- vasculopathy (1)
- velocity (1)
- ventral hernia (1)
- ventricular tachycardia (1)
- vertebral fractures (1)
- viral replication (1)
- virions (1)
- virulence (1)
- visual (1)
- vitamin D (1)
- volume determination (1)
- whole body MRI (1)
- whole-body (1)
- whole-brain radiotherapy (1)
- α-galactosidase A (1)
- α-synuclein (1)
- β1 integrin (1)
Institute
- Medizinische Klinik und Poliklinik I (29)
- Neurologische Klinik und Poliklinik (26)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (19)
- Institut für Klinische Epidemiologie und Biometrie (10)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (10)
- Medizinische Klinik und Poliklinik II (10)
- Pathologisches Institut (10)
- Theodor-Boveri-Institut für Biowissenschaften (9)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (8)
- Klinik und Poliklinik für Nuklearmedizin (8)
Sonstige beteiligte Institutionen
Attention-deficit/hyperactivity disorder (ADHD) is a highly heritable childhood-onset neuropsychiatric condition, often persisting into adulthood. The genetic architecture of ADHD, particularly in adults, is largely unknown. We performed an exome-wide scan of adult ADHD using the Illumina Human Exome Bead Chip, which interrogates over 250 000 common and rare variants. Participants were recruited by the International Multicenter persistent ADHD CollaboraTion (IMpACT). Statistical analyses were divided into 3 steps: (1) gene-level analysis of rare variants (minor allele frequency (MAF)<1%); (2) single marker association tests of common variants (MAF⩾1%), with replication of the top signals; and (3) pathway analyses. In total, 9365 individuals (1846 cases and 7519 controls) were examined. Replication of the most associated common variants was attempted in 9847 individuals (2077 cases and 7770 controls) using fixed-effects inverse variance meta-analysis. With a Bonferroni-corrected significance level of 1.82E−06, our analyses of rare coding variants revealed four study-wide significant loci: 6q22.1 locus (P=4.46E−08), where NT5DC1 and COL10A1 reside; the SEC23IP locus (P=6.47E−07); the PSD locus (P=7.58E−08) and ZCCHC4 locus (P=1.79E−06). No genome-wide significant association was observed among the common variants. The strongest signal was noted at rs9325032 in PPP2R2B (odds ratio=0.81, P=1.61E−05). Taken together, our data add to the growing evidence of general signal transduction molecules (NT5DC1, PSD, SEC23IP and ZCCHC4) having an important role in the etiology of ADHD. Although the biological implications of these findings need to be further explored, they highlight the possible role of cellular communication as a potential core component in the development of both adult and childhood forms of ADHD.
Aims
Sudden cardiac death (SCD) is a major contributor to the excess mortality of patients on maintenance dialysis. Homoarginine deficiency may lead to decreased nitric oxide availability and endothelial dysfunction. Based on this rationale we assessed whether homoarginine deficiency is a risk factor for SCD in dialysis patients.
Methods and results
This study examined the association of homoarginine with cardiovascular outcomes in 1255 diabetic haemodialysis patients from the German diabetes and dialysis study. During a median of 4 years of follow-up, hazard ratios (HR) (95% CI) for reaching the following pre-specified, adjudicated endpoints were determined: SCD, myocardial infarction, stroke, death due to heart failure, and combined cardiovascular events. There was a strong association of low homoarginine concentrations with the presence of congestive heart failure and left ventricular hypertrophy as well as increased levels of brain natriuretic peptide. Per unit decrease in homoarginine, the risk of SCD increased three-fold (HR 3.1, 95% CI 2.0–4.9), attenuating slightly in multivariate models (HR 2.4; 95% CI 1.5–3.9). Patients in the lowest homoarginine quintile experienced a more than two-fold increased risk of SCD, and more than three-fold increased risk of heart failure death than patients in the highest quintile, which accounted for the high incidence of combined cardiovascular events. Low homoarginine showed a trend towards increased risk of stroke, however, myocardial infarction was not meaningfully affected.
Conclusion
Low homoarginine is a strong risk factor for SCD and death due to heart failure in haemodialysis patients. Further studies are needed to elucidate the underlying mechanisms, offering the potential to develop new interventional strategies.
Background:
Fabry disease is an inherited metabolic disorder characterized by progressive lysosomal accumulation of lipids in a variety of cell types, including neural cells. Small, unmyelinated nerve fibers are particularly affected and small fiber peripheral neuropathy often clinically manifests at young age. Peripheral pain can be chronic and/or occur as provoked attacks of excruciating pain. Manifestations of dysfunction of small autonomic fibers may include, among others, impaired sweating, gastrointestinal dysmotility, and abnormal pain perception. Patients with Fabry disease often remain undiagnosed until severe complications involving the kidney, heart, peripheral nerves and/or brain have arisen.
Methods:
An international expert panel convened with the goal to provide guidance to clinicians who may encounter unrecognized patients with Fabry disease on how to diagnose these patients early using simple diagnostic tests. A further aim was to offer recommendations to control neuropathic pain.
Results:
We describe the neuropathy in Fabry disease, focusing on peripheral small fiber dysfunction - the hallmark of early neurologic involvement in this disorder. The clinical course of peripheral pain is summarized, and the importance of medical history-taking, including family history, is highlighted. A thorough physical examination (e. g., angiokeratoma, corneal opacities) and simple non-invasive sensory perception tests could provide clues to the diagnosis of Fabry disease. Reported early clinical benefits of enzyme replacement therapy include reduction of neuropathic pain, and adequate management of residual pain to a tolerable and functional level can substantially improve the quality of life for patients.
Conclusions:
Our recommendations can assist in diagnosing Fabry small fiber neuropathy early, and offer clinicians guidance in controlling peripheral pain. This is particularly important since management of pain in young patients with Fabry disease appears to be inadequate.
Aims
Chondroid lipoma (CL) is a benign tumor that mimics a variety of soft tissue tumors and is characterized by translocation (11;16). Here, we analyze CL and its histological mimics.
Methods
CL ( ) was compared to a variety of histological mimics ( ) for morphological aspects and immunohistochemical features including cyclinD1(CCND1). Using FISH analysis, CCND1 and FUS were investigated as potential translocation partners.
Results
All CLs were strongly positive for CCND1. One of 4 myoepitheliomas, CCND1, was positive. In well-differentiated lipomatous tumors and in chondrosarcomas, CCND1 was frequently expressed, but all myxoid liposarcomas were negative. FISH analysis did not give support for direct involvement of CCND1 and FUS as translocation partners.
Conclusions
Chondroid lipoma is extremely rare and has several and more prevalent histological mimics. The differential diagnosis of chondroid lipomas can be unraveled using immunohistochemical and molecular support.
Background
Comorbidities negatively affect prognosis more strongly in heart failure with preserved (HFpEF) than with reduced (HFrEF) ejection fraction. Their comparative impact on physical impairment in HFpEF and HFrEF has not been evaluated so far.
Methods and results
The frequency of 12 comorbidities and their impact on NYHA class and SF-36 physical functioning score (SF-36 PF) were evaluated in 1,294 patients with HFpEF and 2,785 with HFrEF. HFpEF patients had lower NYHA class (2.0 ± 0.6 vs. 2.4 ± 0.6, p < 0.001) and higher SF-36 PF score (54.4 ± 28.3 vs. 54.4 ± 27.7, p < 0.001). All comorbidities were significantly (p < 0.05) more frequent in HFrEF, except hypertension and obesity, which were more frequent in HFpEF (p < 0.001). Adjusting for age and gender, COPD, anemia, hyperuricemia, atrial fibrillation, renal dysfunction, cerebrovascular disease and diabetes had a similar (p for interaction > 0.05) negative effect in both groups. Obesity, coronary artery disease and peripheral arterial occlusive disease exerted a significantly (p < 0.05) more adverse effect in HFpEF, while hypertension and hyperlipidemia were associated with fewer (p < 0.05) symptoms in HFrEF only. The total impact of comorbidities on NYHA (AUC for prediction of NYHA III/IV vs. I/II) and SF-36 PF (r 2) in multivariate analyses was approximately 1.5-fold higher in HFpEF, and also much stronger than the impact of a 10% decrease in ejection fraction in HFrEF or a 5 mm decrease in left ventricular end-diastolic diameter in HFpEF.
Conclusion
The impact of comorbidities on physical impairment is higher in HFpEF than in HFrEF. This should be considered in the differential diagnosis and in the treatment of patients with HFpEF.
Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson’s disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies.
Background:
Conventional parameters including Ki67, hormone receptor and Her2/neu status are used for risk stratification for breast cancer. The serine protease urokinase plasminogen activator (uPA) and the plasminogen activator inhibitor type-1 (PAI-1) play an important role in tumour invasion and metastasis. Increased concentrations in tumour tissue are associated with more aggressive potential of the disease. Multigene tests provide detailed insights into tumour biology by simultaneously testing several prognostically relevant genes. With OncotypeDX\(^{®}\), a panel of 21 genes is tested by means of quantitative real-time polymerase chain reaction.
The purpose of this pilot study was to analyse whether a combination of Ki67 and uPA/PAI-1 supplies indications of the result of the multigene test.
Methods:
The results of Ki67, uPA/PAI-1 and OncotypeDX\(^{®}\) were analysed in 25 breast carcinomas (luminal type, pT1/2, max pN1a, G2). A statistical and descriptive analysis was performed.
Results:
With a proliferation index Ki67 of < 14%, the recurrence score (RS) from the multigene test was on average in the low risk range, with an intermediate RS usually resulting if Ki67 was > 14%. Not elevated values of uPA and PAI-1 showed a lower rate of proliferation (average 8.5%) than carcinomas with an increase of uPA and/or PAI-1 (average 13.9%); p = 0.054, Student’s t-test. When Ki67 was > 14% and uPA and/or PAI-1 was raised, an intermediate RS resulted. These differences were significant when compared to cases with Ki67 < 14% with non-raised uPA/PAI-1 (p < 0.03, Student’s t-test). Without taking into account the proliferative activity, an intermediate RS was also verifiable if both uPA and PAI-1 showed raised values.
Conclusion:
A combination of the values Ki67 and uPA/PAI-1 tended to depict the RS to be expected. From this it can be deduced that an appropriate analysis of this parameter combination may be undertaken before the multigene test in routine clinical practice. The increasing cost pressure makes it necessary to base the implementation of a multigene test on ancillary variables and to potentially leave it out if not required in the event of a certain constellation of results (Ki67 raised, uPA and PAI-1 raised).
Rats intracerebroventricularily (icv) treated with streptozotocin (STZ), shown to generate an insulin resistant brain state, were used as an animal model for the sporadic form of Alzheimer's disease (sAD). Previously, we showed in an in vivo study that 3 months after STZ icv treatment hippocampal adult neurogenesis (AN) is impaired. In the present study, we examined the effects of STZ on isolated adult hippocampal neural stem cells (NSCs) using an in vitro approach. We revealed that 2.5 mM STZ inhibits the proliferation of NSCs as indicated by reduced number and size of neurospheres as well as by less BrdU-immunoreactive NSCs. Double immunofluorescence stainings of NSCs already being triggered to start with their differentiation showed that STZ primarily impairs the generation of new neurons, but not of astrocytes. For revealing mechanisms possibly involved in mediating STZ effects we analyzed expression levels of insulin/glucose system-related molecules such as the glucose transporter (GLUT) 1 and 3, the insulin receptor (IR) and the insulin-like growth factor (IGF) 1 receptor. Applying quantitative Real time-PCR (qRT-PCR) and immunofluorescence stainings we showed that STZ exerts its strongest effects on GLUT3 expression, as GLUT3 mRNA levels were found to be reduced in NSCs, and less GLUT3-immunoreactive NSCs as well as differentiating cells were detected after STZ treatment. These findings suggest that cultured NSCs are a good model for developing new strategies to treat nerve cell loss in AD and other degenerative disorders.
Background:
During the last years, (19)F-MRI and perfluorocarbon nanoemulsion (PFC) emerged as a powerful contrast agent methodology to track cells and to visualize inflammation. We applied this new modality to visualize deep tissue abscesses during acute and chronic phase of inflammation caused by Staphylococcus aureus infection.
Methodology and Principal Findings:
In this study, a murine thigh infection model was used to induce abscess formation and PFC or CLIO (cross linked ironoxides) was administered during acute or chronic phase of inflammation. 24 h after inoculation, the contrast agent accumulation was imaged at the site of infection by MRI. Measurements revealed a strong accumulation of PFC at the abscess rim at acute and chronic phase of infection. The pattern was similar to CLIO accumulation at chronic phase and formed a hollow sphere around the edema area. Histology revealed strong influx of neutrophils at the site of infection and to a smaller extend macrophages during acute phase and strong influx of macrophages at chronic phase of inflammation.
Conclusion and Significance:
We introduce (19)F-MRI in combination with PFC nanoemulsions as a new platform to visualize abscess formation in a murine thigh infection model of S. aureus. The possibility to track immune cells in vivo by this modality offers new opportunities to investigate host immune response, the efficacy of antibacterial therapies and the influence of virulence factors for pathogenesis.